Sidley represented GE HealthCare (NASDAQ: GEHC) in an exclusive licensing agreement with Lantheus Holdings, Inc. (NASDAQ: LNTH), for GE HealthCare to develop, manufacture, and commercialize Lantheus’ piflufolastat F 18 (PYLARIFY® in U.S. market) in Japan for prostate cancer diagnostics and companion diagnostic use. PYLARIFY is used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.
The agreement includes the transfer of regulatory dossiers, manufacturing competencies, and technical support to enable GE HealthCare to drive clinical development in Japan toward potential regulatory submissions and commercial launch. GE HealthCare will draw on its extensive manufacturing network and R&D expertise following its acquisition in March 2025 of Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan.
The Sidley team was led by Alison Lehner (Technology and Life Sciences Transactions) and included Jean Qiu and Sabrina Glavota (also Technology and Life Sciences Transactions).
Additional information is available in the press release.
